Leukemia, Lymphoma, Myeloma, and Immunotherapy with Dr. Philip Greenberg

Dr. Philip Greenberg discusses how immunotherapy works for blood cancers (leukemia, lymphoma, and multiple myeloma), promising immunotherapy clinical trials, as well as potential side effects. #CRIsummit #Immunotherapy https://www.cancerresearch.org/virtua... More than 175,000 new cases of leukemia, lymphoma, and multiple myeloma are expected this year in the United States. Several immunotherapies are already FDA-approved, and ongoing research demonstrates even greater potential for new treatments, especially in adoptive cell therapy. Join Dr. Philip Greenberg, the head of immunology at the Fred Hutchinson Cancer Research Center, in a Q&A discussion about different immunotherapies used in the treatment of blood cancers and new treatments in development to bring the benefits of immunotherapy to more patients. In this video, Dr. Greenberg describes available immunotherapies for blood cancers, including cell-based therapies like CAR T cell therapy, targeted cancer therapy like bispecific antibodies, and checkpoint inhibitors. He provides an overview future immunotherapy research for blood cancer that includes learning how to best reduce potential side effects for blood cancer patients receiving immunotherapy as well as how these side effects differ from chemotherapy side effects. https://www.cancerresearch.org/immuno... 00:00 – Welcome 01:10 – Introduction of Available Immunotherapy for Blood Cancers 07:39 – The future of cancer immunotherapy research 08:56 – Live Q&A Dr. Greenberg then answers viewer questions about blood cancer and immunotherapy from the audience: What are promising clinical trials available for blood cancer patients, including the latest in leukemia, lymphoma, and multiple myeloma? Where can I access clinical trials? I was recently diagnosed with blood cancer. When should I start to look into clinical trials? How has COVID-19 impacted clinical research? Is it still safe to enroll in a clinical trial? Is the COVID-19 vaccine safe for blood cancer patients? Is it possible to get CAR T cell therapy after having a bone marrow transplant? Are the side effects risks higher? Can I enroll in a blood cancer immunotherapy clinical trial if I have an autoimmune disease? Is age an exclusion criteria for blood cancer immunotherapy clinical trials? What are new immunotherapy clinical trials available for children with blood cancer? Dr. Philip Greenberg is the head of immunology at the Fred Hutchinson Cancer Research Center, and a professor of medicine and immunology at the University of Washington. He is also a member of the CRI Scientific Advisory Council and has earned multiple grants for his laboratory research in immunotherapy. Dr. Greenberg is an internationally recognized expert in cancer immunotherapy, a form of treatment that aims to harness the power of immune cells to eliminate cancer. His early discoveries showed how to target diseases with T cells and helped drive this now-burgeoning field. For these contributions, he was awarded the 2011 William B. Coley Award for Distinguished Research in Tumor Immunology. Now, he is focused on expanding the use of adoptive T cell immunotherapies to other cancers, including acute myeloid leukemia, ovarian cancer, and pancreatic cancer, so that more patients can benefit. https://www.cancerresearch.org/about-... Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law. sync ID: MB01WB7EUVJUBPT